Please login to the form below

Not currently logged in

Novartis endorses Kigali Declaration by investing $250m for tropical diseases

1.7 billion people suffer from neglected tropical diseases worldwide, and there are 241 million cases of malaria


Novartis has endorsed the Kigali Declaration on neglected tropical diseases (NTDs) by announcing a $250m investment over five years to fight against NTDs and malaria.

The declaration aims to increase government support and secure commitments to achieve the SDG3 target on NTDs and to deliver the targets set out in the World Health Organization’s (WHO) Neglected Tropical Disease Roadmap.

Country leaders, including presidents, community and business leaders, and philanthropists attended The Kigali Summit on Malaria and NTDs to renew high-level commitments and to galvanise action to end these diseases.

$100m of the investment will be used to advance research and development of Novartis’ NTD programme, that includes Chagas disease, leishmaniasis, dengue and cryptosporidiosis.

The other $150m will be used to advance the clinical development programmes of its three novel drug candidates to combat the emerging resistance to malaria treatment artemisinin and develop a new formula for babies under 5kg with malaria.

1.7 billion people around the world are affected by NTDs, which are prevalent in tropical areas and mostly affect impoverished communities, causing devastating health, social and
economic consequences.

According to the 2021 World Malaria Report, there were 241 million cases of malaria and 627,000 malaria deaths in 2020. Children under five are particularly at risk, with malaria taking the life of a child every minute in Africa.

Novartis, working with partners, has delivered more than one billion treatments for malaria to date, including more than 450 million paediatric treatments, without profit to malaria-endemic countries.

Van Narasimhan, CEO of Novartis, said: “Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done. Novartis will continue progressing our longstanding commitment to helping realise a world free of NTDs.

“Today, by endorsing the Kigali Declaration and pledging to invest $250m, we aim to accelerate progress toward elimination of these diseases, which continue to cause suffering and stigma for millions of people around the globe.”

Novartis was among the original endorsers of the London Declaration on NTDs in 2012, committing to a multidrug therapy (MDT) donation to support global efforts to eliminate leprosy. A subsequent commitment of $100m was made in 2018 towards the fight against malaria.

Article by
Emily Kimber

23rd June 2022

From: Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...